Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

Germ cell tumors and sex cord stromal tumors can be malignant (cancer) or benign (not cancer). Malignant (muh-LIG-nunt) cancers need treatment. Benign (beh-NINE) tumors are not cancer and do not need ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...